Major Mechanism Driving Kidney Cancer Progression Identified

Research has shown that the shortage of oxygen, or hypoxia, created when rapidly multiplying kidney cancer cells outgrow their local blood supply can accelerate tumor growth.

It can do so by causing a nuclear protein called SPOP-which normally suppresses tumor growth-to move out of the nucleus to the cytoplasm, where it has the opposite effect, promoting rapid proliferation.

Renal Cell Carcinoma-Causes-Risk Factors-Symptoms-Diagnosis-Treatment-Prevention
Renal cell carcinoma is kidney cancer that affects the lining of the kidney tubules. The initial stages of the cancer are asymptomatic and this makes early management of the disease difficult.

In the March 20, 2014, issue of the journal Cancer Cell, researchers from Chicago and Beijing describe the mechanisms that enable hypoxia to cause the overexpression of SPOP. They show that hypoxia also stimulates the shuttling of SPOP out of the nucleus, where it normally prevents tumor growth, to the cytoplasm, where it shuts down protective pathways that should restrict tumor growth.

This cytoplasmic accumulation of SPOP, the authors note, "is sufficient to convey tumorigenic properties onto otherwise non-tumorigenic cells."

"It becomes a vicious cycle," said the study's senior author Kevin White, PhD, professor of human genetics, and ecology and evolution, and director of the Institute for Genomics and Systems Biology at the University of Chicago. "In people with clear-cell renal cell carcinoma, hypoxia-inducible factors enter the nucleus and target the SPOP gene. SPOP gets overexpressed and misdirected to the cytoplasm, where it interferes with multiple systems designed to suppress tumor growth. This encourages tumor growth, leading to more hypoxia."

Cysts and Tumours-Multi cystic Dysplastic Kidneys-Wilms-Testicular
Ultrasound scan reveals multiple cysts and there is no function on that kidney when tested on DMSA scan. A vast majority of them resolve spontaneously.

White and colleagues first recognized a role for SPOP (speckle-type POZ protein) as a biomarker for kidney cancer in 2009. They found that 99 percent of clear cell renal cell cancers (ccRCC, the most common type of kidney cancer) had elevated SPOP levels. So they began to study the connection between increased SPOP production and ccRCC.

Kidney cancer is a significant health problem. It is the eighth most common malignancy in the United States, causing almost 64,000 new cases in 2014 and nearly 14,000 deaths. Worldwide, it causes more than 200,000 new cases annually and 100,000 deaths.

Acute Renal (Kidney) Failure- Causes, Symptoms, Diagnosis, Treatment and Complications
Acute renal failure is the sudden cessation of the functioning of kidneys, that can be due to reduced renal blood flow, damage to renal tissues.

The high mortality is linked to late detection. There are no good screening tests, so most kidney cancers are diagnosed late, only after there is blood in the urine. Approximately 30 percent of RCC patients in the U.S. have metastatic disease when first diagnosed and nearly half of the remaining 70 percent will develop metastases. The disease is highly resistant to chemotherapy.

Understanding how misplaced but not mutated SPOP contributes to cancer growth, the researchers hope, might point to new ways to intervene. Previous work from White's laboratory on the fruit-fly version of SPOP suggested that it was a key regulatory hub, one that influenced several cancer-related pathways.

Diabetic Kidney Disease - Symptoms, Signs, Causes, Diagnosis, Stages & Treatment
Diabetic nephropathy refers to kidney damage due very high levels of blood sugar levels in diabetics.

When the researchers shifted their focus from flies to human cancers they found that the high levels of SPOP in the cytoplasm had a profound effect. It degraded multiple regulatory proteins there that ordinarily served to suppress tumor growth.

The most important was PTEN, a gene that is damaged or lost in several types of cancer. The researchers found that cells from tumor samples had consistently high levels of SPOP and low levels of PTEN. Normal tissues from the same patient had low SPOP and high PTEN. SPOP could also degrade several other tumor-suppressor proteins, removing additional barriers to rapid tumor growth.

"These results clearly demonstrate that SPOP is acting as a critical hub in a network involving multiple cancer-related pathways," the authors wrote. "In doing so, SPOP appears to be both necessary and sufficient for tumorigenic phenotypes."

"We found that this normal protein, found in the wrong place and acting in the wrong way, was sufficient to drive the formation of tumors," White said. "Just by putting SPOP into the cytoplasm, we got great big tumors. But we also saw that the cells get addicted to it. When we knock it down, they die. Our hope is that cytoplasmic SPOP might turn out to be a good drug target."

The National Institutes of Health, the Beijing Science Foundation, the Keck Foundation, the Chicago Community Trust and the SPOP funded this study.

Additional authors include former University of Chicago Institute for Genomics and Systems Biology postdoc Jiang Liu and his team in Beijing that included Guoqiang Li, Weimin Ci, Ke Chen, Zhixiang Fan, Zhongqiang Guo, Jing Zhang, Yuqwen Qe, Lu Wang, Nin Zhuang, Xuesong Li, Liquon Zhou, Xianghong Li and Yong Tian; Shengdi Hu from University of California at San Francisco; Subhradip Karmakar, Ruby Dhar, Sandip Prasad, Carrie Rinker-Schaeffer, Scott Eggener and Thomas Stricker from the University of Chicago; and Matthew Calabrese, Edmund Watson and Brenda Schulman from St Jude Children's Research Hospital, Memphis.

Source-Newswise